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ABSTRACT
Objective: The measurement of pancreatic elastase (PE) in feces is used
widely to screen for pancreatic exocrine insufficiency. The aim of our
study was to evaluate the relationship of PE with residual beta cell
secretion and metabolic control in patients with diabetes mellitus.
Method: We determined the presence of PE in specimens via enzyme-
linked immunosorbent assay (ELISA), whereas serum fasting glucose, C-
peptide, amylase, lipase, triglycerides, total 25(OH)-vitamin D, C-reactive
protein (CRP), and hemoglobin A1c (HbA1c) concentrations were assayed
using routine laboratory tests.
Results: PE values in 48 patients with diabetes were significantly lower
than in 24 healthy volunteers (P¼ .001). In one-third of participants with
diabetes mellitus, PE were less than 200 mg per g, indicating pancreatic
functional insufficiency. Among the patients in the cohort, PE correlated
positively with C-peptide levels (P¼ .04), lipase (P¼ .009), CRP
(P¼ .04), sex (P¼ .03), and BMI (P¼ .02) but not significantly with
duration of diabetes (P¼ .81) or levels of HbA1c (P¼ .87), amylase
(P¼ .06), total 25(OH)-vitamin D (P¼ .16), or triglycerides (P¼ .52).
Conclusion: Our results demonstrated a strong association of diabetes
with low PE levels.
Keywords: pancreatic elastase, pancreatic exocrine insufficiency, dia-
betes mellitus, feces, ELISA, biomarker
Despite the large functional reserve of the exocrine pancreas,
which was estimated to be 3 times larger than the functional
reserve of the endocrine pancreas, we discovered an
insufficient level of pancreatic exocrine function in a significant
percentage of patients with diabetes mellitus. The molecular
basis for this phenomenon is not completely clarified,
particularly regarding the type of cell that is the source of the
disease and the basic pathological process. Several
pathophysiological concepts and hypotheses have been
suggested1-7 in various attempts to explain the dysfunction of
the exocrine pancreatic function in patients with diabetes.
The aim of this study was to determine the frequency and
level of exocrine pancreatic function insufficiency in the
patients with type 1 and type 2 diabetes mellitus (T1DM and
T2DM, respectively), by determining the concentration of
pancreatic elastase (PE) in the feces. As an indirect assay for
evaluation of pancreatic exocrine function, PE testing has
become a standard diagnostic tool with good correlation to
the results of direct functional tests and morphological
changes in the pancreas discovered via imaging
techniques.8,9 The main disadvantage of determining
concentration of PE is low sensitivity in mild to moderate
insufficiency.10 Another limitation of the clinical usefulness of
PE is posed by the difficulty in differentiating pancreatic from
nonpancreatic malapsorption.11 In assessing the level of
insufficiency of exocrine pancreatic function, we applied the
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standard cut-off value, determined based on a large group
of patients with exocrine pancreatic insufficiency of different
etiologies. According to the applied cut-off value, values
between 100 mg per g and 200 mg per g of feces indicate
mild to moderate insufficiency of exocrine pancreatic function,
and values between 100 mg per g and 20 mg per g of feces are
associated with severely reduced function, whereas values
below 20 mg per g of feces are referred to as indicating
extremely reduced exocrine pancreatic function.
To assess the significance of PE levels in the studied group
with diabetes, we examined the connection between PE levels
and glucose metabolism based on fasting serum glucose and
hemoglobin A1c (HbA1c) levels as indicators of metabolic
control. Also, to assess the trophic role of insulin in pancreatic
exocrine cells, we determined the connection between PE
levels in the feces and the concentration of C-peptide in the
serum as a measure of the residual function of pancreatic b-
cells. We examined the secretory function of the exocrine
pancreas in patients with diabetes by recording levels of
amylase and lipase, as well as by investigating the possible
connection of these enzymes with PE levels in feces. We
measured C-reactive protein (CRP) as an indicator of the
acute inflammation phase, to evaluate the inflammatory status
of the pancreas in an attempt to detect the stage of
deterioration of endocrine and exocrine pancreatic
dysfunction. By determining the values of triglycerides, we
evaluated the involvement of altered lipid metabolism in the
pathogenesis of exocrine pancreatic function insufficiency.
We examined the prevalence of insufficient concentrations of
total 25(OH)-vitamin D in patients with diabetes and the
possible connection between low levels of PE in the feces and
insufficient levels of total 25(OH)-vitamin D, as a measure of
qualitative malnutrition, with respect to lipids. Further, we
estimated the interconnection and prognostic significance of
analyzed biochemical parameters on the PE levels in feces.
Also, we evaluated a possible correlation between levels of PE
with the age and sex of patients, duration of diabetes, and
diabetes type in the group of patients with diabetes.
Materials and Methods
In this article, we cover a population of patients with
diabetes who underwent a routine checkup to the Clinic for
Endocrinology, Diabetes and Metabolic Disorders, Clinical
Center of Serbia in the period from June 2009 through
October 2009. The study population comprises a cohort of
48 patients (30 women and 18 men) aged 22 years to 82
years. In the group of patients with diabetes, there were 10
patients with T1DM and 38 with T2DM. The duration of
illness ranged from 1 year to 36 years, with a median of 12
years. During this study, 33 patients were taking insulin
therapy, 12 patients used oral antidiabetic drugs, and 3
patients were taking combination drug therapy. Our study
also included a control group that consisted of 24 healthy
volunteers (20 women and 4 men) aged 25 years to 76
years. This group consisted of persons without diabetes or
any presence of chronic or acute diseases of the
gastrointestinal tract. We collected specimens of blood and
feces from the control group from July 2009 through
October 2009.
Blood specimens were collected between 7 AM and 10
AM, after a period of fasting. After venipuncture and the
time required for coagulation, we centrifuged the blood
specimens for 15minutes at 1500 g at room temperature.
Serum aliquots were separated and immediately frozen
at -70 C until determination of C-peptide, glucose, lipase,
amylase, total 25(OH)-vitamin D, triglycerides, and CRP.
HbA1c was measured on the same day from whole blood
specimens with ethylenediaminetetraacetic acid disodium
(EDTA-Na2) as an anticoagulant. After the stool specimens
arrived at the laboratory, they were stored at -20 C until
the extraction and determination of PE. According to the
manufacturer instruction, the specimen size was greater
than the minimum required and the stool specimens were
well formed (ie, they were not of watery consistency). We
performed PE extractions, following instructions provided
by the kit manufacturer. Extracts of stool specimens were
tested in duplicate; results were reported as the mean of
the 2 measurements. Procedures of extraction and
determination of PE were repeated in all specimens with
borderline or low PE results.
PE levels were determined using a “sandwich” enzyme-
linked immunosorbent assay (ELISA) kit, which combines the
use of 2 monoclonal antibodies that are specific to human
PE (ScheBoBiotech AG). Biochemical parameters were
analyzed by using commercial tests because they are
available on 2 analyzers: the integrated biochemical and
immunochemical analyzer ci8200 Architect (Abbott
Laboratories Inc) and the multichannel immunochemical
analyzer Cobas e601 (F. Hoffman-La Roche Ltd). We
regularly checked the reliability of the measurement results
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through assessment of appropriate controls and application
of the internal quality control principle.
Statistical computer programs SPSS, version 11.5 for
Windows (SPSS, Inc) and MedCalc, version 9.5.2.0
(MedCalc Software bvba) were used for the statistical
analysis and to produce the resulting data charts. P<.05
was determined to show statistical significance.
Results
For within-run imprecision evaluation, 3 feces samples were
determined to have low (130 mg/g of feces), borderline low
(225 mg/g of feces), and normal (479 mg/g of feces) PE
values, for 15 replicates per run. The coefficients of variation
(CVs) that we obtained were 7.5%, 6.9%, and 4.8%,
respectively. We calculated the between-run imprecision
from measuring PE in 3 homogenates of specimens with
values of 966 14.1, 2036 17.3, and 3516 27.4 mg/g of feces
for 10 consecutive days. The resulting CVs were 14.6%,
8.5%, and 7.8%, respectively. Method inaccuracy was
evaluated using the commercial control material with
assigned value of 200 mg PE per g of feces. Concentration of
PE was determined in 15 replicates, and the obtained mean
and the assigned value were not significantly different
according to the results of the Student’s t-test (P ¼ .18). The
linearity of the PE ELISA assay was determined with the
concentration of the lowest and highest standard, which
were 15 mg and 500 mg PE per g of feces, respectively.
Table 1 includes the baseline demographic and clinical
characteristics of the study participants divided into a group
with diabetes and a group of healthy volunteers (control
group). For comparison of data collected for sex, age, and
body mass index (BMI) between the control and diabetes
groups, we used the nonparametric Pearson chi-square test.
In the control group, there were more women than in the
group with diabetes, but that difference was not statistically
significant (P¼ .07). The studied groups also did not
statistically differ by age (P¼ .08) or by BMI (P¼ .11).
For normal distribution, we used the Shapiro-WilkW test.
The skewness of data for determined parameters in the
diabetes and control groups is represented in Table 1. For
Table 1. Baseline Demographic and Clinical Data Distribution of Patients With Diabetes and Control
Individuals and the Skewness of Data for Determined Parameters in the Studied Groups
Variable Patients With Diabetes
(n¼ 48)
Control Individuals
(n¼ 24)
Median (IQR) P Valuea Median (IQR) P Valuea
Age (y) 61 (20) .02 50 (21) .84
Sex
Male 18 (37.5) 4 (16.7)
Female 30 (62.5) 20 (83.3)
Type of diabetes
Type 1 10 (21) NA
Type 2 38 (79) NA
Duration of diabetes (y) 12 (15) .02 NA NA
Body mass index (kg/m2) 26 (6) <.001 24 (6) .53
Pancreatic elastase (lg/g) 386 (498) <.001 648 (481) .04
C-peptide (pmol/L) 311 (542) <.001 460 (223) <.001
Glucose (mmol/L) 8.7 (4.5) .07 4.9 (0.6) .06
HbA1c (%) 9.2 (2.7) .49 5.1 (0.7) .50
Amylase (U/L) 46 (30) .04 59 (34) .03
Lipase (U/L) 22 (26) <.001 22 (15) .02
Triglycerides (mmol/L) 1.58 (1.13) <.001 1.14 (0.64) .10
C-reactive protein (mg/L) 1.82 (5.81) <.001 0.71 (1.91) <.001
Total 25(OH)-vitamin D (mg/L) 17.2 (14.6) .14 23.8 (16.4) .13
NA, not applicable; IQR, interquartile range; HbA1c, hemoglobin A1c.
aP> .05 indicates normal distribution (Shapiro-Wilk W test).
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comparison of continuous variables between the 2 studied
groups, we used the Student’s t-test if the distribution was
normal and the nonparametric Mann-Whitney U-test test for
skewed continuous variables. Compared with the control
group, patients with diabetes had significantly lower values
(Mann-Whitney U-test, P<.05) of PE (P¼ .001), C-peptide
(P¼ .03), and amylase (P¼ .02) but significantly higher levels
of CRP (P¼ .004) and triglyceride (P¼ .001), whereas lipase
values did not differ significantly (P¼ .81). Values of total
25(OH)-vitamin D in the diabetes group were significantly
lower among patients with diabetes (Student’s t-test, P<.05)
than in the control group (P¼ .001), whereas levels of glucose
and HbA1c were significantly higher (P<.001). The distribution
of determined values of all the examined parameters in the 2
groups is shown graphically in Figure 1.
The existence and degree of correlation between the 2
parameters in the group of patients with diabetes was tested
by using the Spearman nonparametric correlation analysis.
The aim was to investigate whether there is a correlation
between the observed variables and if so, to what significance
of correlation is the agreement. We set the Spearman
correlation coefficient to establish links between PE levels and
other biochemical parameters, as well as certain patient
characteristics in the group with diabetes. The results of
correlations between concentrations of PE and the studied
parameters are summarized in Table 2. The results showed
that the values of PE for patients with diabetes were
significantly positively correlated with levels of C-peptide,
lipase, and CRP; BMI; and sex. However, the obtained
correlation coefficients are between 0.25 and 0.50, indicating a
low degree of correlation.
By applying multiple regression analysis with all variables
entered into the model, we showed that combined levels of
amylase and CRP, along with age and BMI, significantly
predict the concentration of PE among patients with diabetes.
We selected the stepwise regression analysis method to use
in analyzing our data. The variables were checked after
introduction into the model and possibly turned off if they
became statistically insignificant. The results of multiple
regression analysis are shown in Table 3.
Discussion
Reduced exocrine pancreatic function in patients with
diabetes was observed in several studies,12-15 some of
which were conducted more than 20 years ago. These
studies used direct measurement of pancreatic enzymes in
duodenal aspirate or measurement of the concentration of
immunoreactive trypsin, lipase activity, amylase, and
pancreatic isoamylase activity in the serum and
measurement chymotrypsin in the feces. High prevalence of
exocrine pancreatic insufficiency in patients with diabetes
was confirmed in many studies based on the determination
of PE in the feces.16-26 PE values below 100 mg per g were
found in 11% to 30% of patients with T1DM and in 3% to 20%
of patients with T2DM.
In the current study, we obtained significantly lower PE values
in the group with diabetes than in the control group. A PE level
of less than 100 mg per g was found in 14% of patients with
diabetes, whereas values of less than 200 mg per g were
obtained in 33% of patients with diabetes and in 4% of healthy
volunteers. Values below 200 mg per g were obtained in 3 of
10 patients with T1DM and in 13 of 38 patients with T2DM.
Some believe that diabetes secondary to illness(es) of the
pancreas (diabetes type 3c) is often mistakenly classified at
diagnosis as being some other type of diabetes.
A reclassification study of 1868 patients with diabetes27
found that a high percentage of patients met diagnostic
criteria for the classification in a group with type 3c diabetes
(9.2%). Previous assessments claimed that type 3c diabetes
accounts for only 0.5% to 1.15% of all cases of diabetes.
These estimates date back to the 1960s and 1980s and
probably deviate from the correct value because evaluation
of the exocrine pancreas at that time was limited to highly
invasive procedures (such as direct functional tests and
endoscopic retrograde cholangiopancreatogram [ERCP]). If
the 9.2% reclassification finding is confirmed by prospective
studies, it will be likely to significantly change the current
view of the epidemiology of diabetes. Consequently, based
on these results, the evaluation of exocrine pancreatic
function and morphologic characteristics should be included
in the clinical workup of with patients with diabetes at least
during the manifestation of the disease because pancreatic
diabetes differs significantly in management challenges
compared with T1DM and T2DM. Severe type 3c diabetes is
commonly referred to as brittle diabetes due to a
combination of persistent mild hyperglycemia and frequent
episodes of hypoglycemia associated with increased
peripheral and decreased hepatic sensitivity to insulin.28
In our research, we obtained a significantly higher
percentage of low values of PE in men (55%) than in women
(20%), in agreement with the earlier results, which found that
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Figure 1
Distribution of values of all the examined parameters in the patients with diabetes and control individuals. Data are presented as box-and-
whisker plots showing 25th, median (50th), and 75th percentile of the distribution. HbA1c indicates hemoglobin A1c; CRP, C-reactive protein;
BMI, body mass index.
Science
144 Lab Medicine 2016;47:2;140–148 www.labmedicine.com
144 DOI: 10.1093/labmed/lmw015
D
ow
nloaded from
 https://academ
ic.oup.com
/labm
ed/article-abstract/47/2/140/2937893 by Belgrade U
niversity user on 30 July 2019
the risk of having PE value of less than 100 mg per g is 3 to 4
times higher18 and 2 times higher19 in men than in women.
This finding is often connected to increased alcohol
consumption among male subject individuals, which may
lead to higher incidence of subclinical chronic pancreatitis.29
In this study, we found no relationship between low PE
values and duration of diabetes. Data in the literature are
discordant regarding this relationship. Our results agree with
those of some studies,19,21,23-25 but other study results
associate duration of diabetes with PE values of less than
200 mg per g.18,20,22 In some studies, duration of diabetes
was associated with exocrine failure in patients with T1DM
but not in those with T2DM, linking it with the ethiology of the
endocrine failure.16 In our study, the cohort group was
comprised of patients with T1DM and those with T2DM, with
an almost 4-fold greater prevalence of participants with
T2DM. This could be the reason why the influence of the
duration of diabetes was not demonstrated. The influence of
diabetes duration on the level of PE is often associated with
a progressive reduction of b-cell function with time and
consequent disorder of blood-glucose control. However, the
results of monitoring studies of pancreatic exocrine function
in patients with T1DM have shown that exocrine pancreatic
insufficiency is not a clinically significant late complication of
T1DM because the results of pancreosimin-secretin testing
of more than 80% of patients with initially normal pancreatic
function remained normal after a follow-up period of 11
years.30 In the same study, it was observed that the
disturbance of pancreatic exocrine function was generally
mild. In most patients, the reduction of secretion of lipase
was higher than 10% of the normal level, so usually,
steatorrhea did not occur, and enzyme replacement
therapy was not required. The authors concluded that mild
to moderate exocrine pancreas failure may occur at
an early stage of autoimmune diabetes and does not progress.
In this study, we found that the BMI value for patients with
diabetes positively correlated with PE values. A greater
percentage of patients with BMI of less than 25 kg per m2
had a low PE value, which is consistent with the results of
some studies.20,25,26 This finding may be explained by
exocrine insufficiency leading to malassimilation. Another
study19 used cut-off values of BMI less than 27 kg per m2 to
show that patients with diabetes and low body weight have
2-fold higher likelihood of having PE values below 100 mg per
g. However, some studies did not find a significant
connection.22-24 Moreover, in other studies,21,31 a negative
correlation was found (ie, lower values of PE were found) in
persons with diabetes who also have obesity. Because most
patients with T2DM have obesity, this finding does not agree
with a general belief that failure of exocrine pancreatic
functioning leads to a loss of body weight. These researchers
concluded that the low values of PE in the group with diabetes
and obesity were obtained due to the low specificity of the
test. However, there is a possibility that obesity and diabetes
have a significant synergistic effect on the development of
exocrine pancreatic function insufficiency.
Several similar studies have assessed metabolic control of
diabetes expressed by HbA1c, with various outcomes. For
example, in a study of patients with T2DM, poor glycemic
control (HbA1c 7.0%) was associated with a higher
probability of obtaining low PE values.19 The assumption is
that the lack of digestive enzymes leads to poor digestion
and intraluminary malabsorption, followed by poor control of
blood-glucose levels. We found no relationship between
HbA1c values and PE levels, in agreement with the findings of
certain studies.23-25 However, other studies22,26 showed an
inverse correlation between these 2 variables.
In this study we found a significant positive correlation
between PE levels in feces and the concentration of C-
peptide in serum as a marker of residual b-cell secretion,
which is consistent with the results of certain studies.22,26 In
this study, 42% of patients with C-peptide values below the
reference method values (<260 pmol/L) had also low levels
Table 2. Correlation Between the Concentration
of Pancreatic Elastase and Other Studied
Parameters in the Group of Patients With
Diabetes
Parameter Pancreatic Elastase (lg/g of Stool)
q Valuea P Valueb
Sex 0.311 .03
Diabetes type 0.009 .95
Age (y) 0.134 .36
Diabetes duration (y) 0.037 .81
BMI (kg/m2) 0.337 .02
C-peptide (pmol/L) 0.297 .04
Glucose (mmol/L) 0.122 .41
HbA1c (%) 0.025 .87
Amylase (U/L) 0.273 .06
Lipase (U/L) 0.373 .009
Triglycerides (mmol/L) 0.094 .52
C-reactive protein (mg/L) 0.302 .04
Total 25(OH)-vitamin D (mg/L) 0.207 .16
aIndicates Spearman correlation coefficients; BMI, body mass index; HbA1c,
hemoglobin A1c.
bBolded values of P<.05 indicate a significant correlation between the parameters.
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of PE. One study22 concluded that in patients with C-peptide
less than 160pmol per L, levels of PE were approximately
50% lower compared with patients with diabetes who have
C-peptide values higher than 160 pmol per L (211 mg/g vs
424 mg/g), whereas the PE values in patients with diabetes
and C-peptide values higher than 160pmol per L were
similar to those obtained in the control group. The same
study suggests that a C-peptide value of higher than
160pmol per L can be considered a cut-off point, above
which endocrine pancreatic function does not damage
exocrine function in T1DM. However, normal PE values in
some patients with C-peptide values lower than 160pmol
per L indicate that insulin secretion is not the only factor that
determines PE level in patients with T1DM.
In our study we found that patients with diabetes have a
significant association between fecal PE levels and serum
lipase activity, but amylase activity was not significantly
correlated with PE. The amylase activity was significantly
lower in the patients with diabetes than in the control group
(51U/L vs 65U/L); this finding is consistent with those of
other studies.32,33 One study34 found reduced serum levels
of lipase in patients with T1DM only. The disruption in
amylase and lipase activity in patients with diabetes
suggests that the determination of pancreatic enzymes in
this group of patients could be a useful marker in assessing
disease progression.
Researchers agree that increased levels of CRP are common
in patients with T2DM, gestational diabetes, and metabolic
syndrome, and that there is a significant correlation between
CRP and the development of T1DM and T2DM. However, in
this study we found a significant positive correlation between
low PE values in stool specimens and low serum CRP levels
in the group of patients with diabetes (Tables 2 and 3).
Among the 14 patients with PE values below 200mg per g in
their stool specimens, we discovered that 11 have CRP
values lower than 5mg per L. Another study35 found
increased levels of inflammatory markers in 7 of 28 patients
with chronic pancreatitis; also, higher values were found in
patients who were at the disease relapse stage. That study
concluded that CRP in chronic pancreatitis reflects the
inflammatory status of the gland. In our study we found that
as many as 6 of 7 patients with PE values lower than 100 mg
per g of stool specimen have CRP values lower than 1 mg
per L. We concluded that low levels of CRP in patients with
low PE values are associated with advanced stages of
insufficient exocrine pancreatic function when the process of
fibrosis of the pancreas has advanced and is not associated
with acute tissue inflammation. However, this conclusion
requires confirmation in further trials.
The results of many cellular and animal studies and some
human studies have linked 25(OH)-vitamin D deficiency with
the pathophysiology of diabetes, suggesting that 25(OH)-
vitamin D replacement therapy might be beneficial in this
context.36,37 We found significantly lower levels of total
25(OH)-vitamin D in the experimental group of patients with
diabetes, compared with the control group (mean, 16.7 vs
26.1mg/L); this finding is in agreement with data from the
literature.38,39 In our study we found that having a level of
total 25(OH)-vitamin D lower than 20mg per mL is more
frequent among individuals with T2DM than in those with
T1DM (68% vs 50%, respectively). Di Cesar et al39 found a
higher prevalence of 25(OH)-vitamin D deficiency in patients
with T2DM (63.5%), compared with a group of patients with
T1DM (36%). In the present study, there was no significant
association between BMI and levels of 25(OH)-vitamin D,
despite that many studies40-42 have found that in obese
patients, 25(OH)-vitamin D accumulates in adipose tissue,
Table 3. Results of Multiple Regression Analysis
PE Value, Dependent Variable (mg/g of stool)
Predictor Variable b B (95% CI) P Valuea
Amylase (U/L) 0.45 6.69 (3.13 – 10.25) <.001
C-reactive
protein (mg/L)
0.32 9.73 (1.16 – 18.3) .03
Age (y) 0.32 6.82 (-12.02 – -1.62) .01
BMI (kg/m2) 0.38 21.25 (5.54 – 36.72) .009
Intercept (constant) NA 160.58 (-644.62 – 323.490) .51
PE, pancreatic elastase; B (95% CI), unstandardized coefficient with 95% confidence interval; b, standardized coefficient; BMI, body mass index; NA, not applicable.
a P<.05 indicates a significant predictor. R2-adjusted: 0.39; F: 8.49; P <.001.
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leading to low levels of 25(OH)-vitamin D in the circulation. A
higher percentage of patients with T2DM are obese,
compared with patients with T1DM, which may partly explain
the higher prevalence of 25(OH)-vitamin D deficiency in
patients with T2DM. Most patients with diabetes take
multivitamin supplements that contain 25(OH)-vitamin D. Di
Cesar et al39 found that as many as 72% of patients with
25(OH)-vitamin D deficiency take multivitamins as a form of
25(OH)-vitamin D supplementation. This paradox may be
explained by the lack of pancreatic exocrine function found
in a large percentage of patients with diabetes. Patients with
exocrine pancreatic insufficiency absorb only approximately
40% of the 25(OH)-vitamin D in the intestinal tract, whereas in
healthy subjects, this rate is 80% to 90%.
In patients with diabetes, exocrine pancreatic function
insufficiency can cause a characteristic clinical picture
(diarrhea with steatorrhea and weight loss) and metabolic
instability that require the constant modification of insulin
therapy. In these cases, due to the risk of malnutrition and
compromised quality of life due to gastrointestinal
discomfort, it is important to start with treatment of exocrine
pancreatic insufficiency, including lipid-soluble 25(OH)-
vitamin D deficiency. In clinical practice, little attention is
given to the fact that insufficient exocrine pancreatic function
has been found in 10% to 40% of patients with diabetes,
compared with approximately 4% of individuals without
diabetes. The clinical relevance of exocrine pancreatic
insufficiency expressed by the PE deficiency in patients with
diabetes has been questioned based on a claim that it is a
mild to moderate condition that does not progress.10,30 The
lack of visible clinical symptoms of exocrine pancreatic
insufficiency is used as an argument for denying its
importance in diabetes. Also, patients with increased
excretion of lipids, manifested as increased presence of fats
in the stool, usually do not spontaneously report abdominal
symptoms. However, when a direct question on this subject
is included in a clinical interview or a questionnaire, some
patients report symptoms such as soft stools, bloating, and
abdominal pain. Most of these patients showed
improvement in abdominal symptoms after the start of
replacement therapy with pancreatic enzymes.
The present study has some limitations that should be
acknowledged and discussed. First, the study population
was heterogeneous with respect to age, sex, type of
diabetes, and duration of diabetes. Underlying diseases
other than diabetes, such as chronic pancreatitis, cystic
fibrosis, cholelithiasis (gallstones), and pancreatic cancer,
could have contributed to the abnormal PE findings.
Although in this study we did not collect information about
diseases other than diabetes, some conclusions might be
inferred on the basis of the available laboratory results. Only
4 patients with diabetes had creatinine levels higher than the
normal value of 110lmol per L, which suggests that most of
the patients included in this study did not have advanced
kidney disease. Further, only 4 patients had gamma-
glutamyltransferase (GGT) values that were higher than
normal (35U/L for women and 55U/L for men), which
suggests that most likely, the majority of patients were not
heavy alcohol users and did not have alcoholic cirrhosis or
posthepatic biliary obstruction. Lack of information on
multivitamin supplements taken by our cohort individuals is
another limitation of this study, which could affect the
accuracy of our vitamin-D-status estimation. Finally, given
the small sample size of the study population, possible
insufficient statistical power in the present study should be
taken into consideration during interpretation of results.
The main result of the present study is that, according to our
measurements of the levels of PE in feces, exocrine
pancreatic function is often decreased in patients with
diabetes. We found that C-peptide, lipase, and CRP levels,
as well as sex and BMI, correlated with PE among the
parameters that we analyzed. Although insufficient levels of
exocrine pancreatic function are common in patients with
diabetes, the clinical significance of this dysfunction remains
a controversy. Therefore, we support suggestions that
analysis of exocrine pancreatic function can be beneficial
for patients with diabetes if they also experience
sudden deterioration in control of glucose metabolism,
weight loss, or symptoms of gastrointestinal disorder of
unknown origin. LM
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